{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Bent A"],"funding":["NCI NIH HHS","NIH"],"pagination":["5449-5451"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9447989"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["27(20)"],"pubmed_abstract":["Circulating tumor DNA (ctDNA) has emerged as a noninvasive diagnostic and prognostic tool for colorectal cancer. Here, we discuss studies that evaluate the ability of plasma-only ctDNA assays to detect minimal residual disease and the potential benefit of integration of methylation into ctDNA assays.<i>See related articles by Parikh et al., p. 5586 and Taieb et al., p. 5638</i>."],"journal":["Clinical cancer research : an official journal of the American Association for Cancer Research"],"pubmed_title":["Going with the Flow: The Promise of Plasma-Only Circulating Tumor DNA Assays."],"pmcid":["PMC9447989"],"funding_grant_id":["R01CA184843","R01CA218230","R01 CA218230","P30CA16672","P50CA221707","P50 CA221707"],"pubmed_authors":["Kopetz S","Bent A"],"additional_accession":[]},"is_claimable":false,"name":"Going with the Flow: The Promise of Plasma-Only Circulating Tumor DNA Assays.","description":"Circulating tumor DNA (ctDNA) has emerged as a noninvasive diagnostic and prognostic tool for colorectal cancer. Here, we discuss studies that evaluate the ability of plasma-only ctDNA assays to detect minimal residual disease and the potential benefit of integration of methylation into ctDNA assays.<i>See related articles by Parikh et al., p. 5586 and Taieb et al., p. 5638</i>.","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Oct","modification":"2025-05-29T16:11:47.686Z","creation":"2025-04-04T09:32:29.589Z"},"accession":"S-EPMC9447989","cross_references":{"pubmed":["34389607"],"doi":["10.1158/1078-0432.CCR-21-2181","10.1158/1078-0432.ccr-21-2181"]}}